PPT-Is it possible? HCV Elimination

Objectives Define elimination as it relates to infectious diseases Understand the gaps in the current cascade of care for HCV Identify interventions required to achieve HCV elimination in a defined population. . Competing Reactions. Alkyl halides can react with Lewis bases by . nucleophilic substitution and/or elimination.. C. C. H. X. +. Y. :. –. C. C. Y. H. X. :. –. +. C. C. +. H. Y. X. :. –. +. . 7-7. Strong bases effect bimolecular elimination.. At higher concentrations of strong base, the rate of alkene formation becomes proportional to both the starting halide and the base.. Under these conditions the second order kinetics are called bimolecular elimination or E2.. Marie-Louise Vachon, MD, . MSc. Division of . Infectious. . Diseases. Centre Hospitalier Universitaire de Québec. Management of HCV . in Co-Infected Patients. Prevention and counselling. Baseline laboratory testing. Mark Sulkowski, MD . Professor of Medicine. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/ Hepatology. Johns Hopkins Medical Institutions. Baltimore Maryland USA. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. Graph-Based Perspective. Probabilistic. Graphical. Models. Inference. Initial Graph. C. D. I. S. G. L. J. H. D. C. D. I. S. G. L. J. H. D. Elimination as Graph Operation. Eliminate: C. C. D. I. S. G. HIV Coinfection & HCV . GT 1,2,3. PHOTON-1 Trial. Phase . 3. Sulkowski. MS, et al. JAMA. 2014;312:353-61.. Treatment. Naïve and Treatment . Experienced. HIV Coinfection. Source: . Sulkowski. MS, et al. JAMA. 2014;312:353-61.. ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. Amber Wheeler, MD. WIHS Scientific Meeting. June 30, 2014. Objectives. To discuss:. Background . Aims. Preliminary “rough” data. Future Directions. HIV-infected . persons have increased. odds of . IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . Co-Infection – Florida, . 2013. . STD and Hepatitis Section in collaboration with HIV/AIDS Section – Surveillance Unit . Division of Disease Control and Health Protection. HIV Disease data from 1981 through December . seroconversion. and genetically linked HCV infections .  . Co-Authors: . H. . Guarino. , R. . Almenana. , E. . Goodbody. , C. . Salvati. .. Presenter: . Pedro . Mateu-Gelabert. , Ph.D. . CUNY- Graduate School of Public Health & Health Policy. What will it take to achieve?. HIV and Co-infections. Marina Klein, MD, MSc, FRCP(C). Chronic Viral Illness Service. McGill University Health Centre. Conflict of interest disclosure. Grants for investigator-initiated studies: . Mark . Gillyon-Powell. Head of the HCV Elimination Programme, NHS England . #. HepCEliminationLondon. Hep C Elimination in Prisons. Be ambitious, and leave no one behind. Mark Gillyon-Powell. Head of Programme – HCV Elimination .